Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > Gud should response on the next PR!!
View:
Post by JTDOUBLE on Oct 22, 2020 12:56pm

Gud should response on the next PR!!

Gud stock acting well now !!

Any good PR this should gap up good !! 

Like I said earlier we should see 8 bucks soon !! 

Keep loading cowgirls and cowboys!!

Comment by Benedict16th on Oct 22, 2020 3:42pm
GT we have seen good PR "We haven't had that spirit here since 1969"
Comment by Snowballgrowth on Oct 22, 2020 5:06pm
A good one:) Of course the expectations are very low so ...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities